JPRN-jRCT2031230419尚未招募1 期
A Phase 1, Multicenter, Open-label, Dose-escalation Study Evaluating the Safety and Tolerability of Intravenous KK2269 Monotherapy and Combination Therapy with Docetaxel in Adult Participants with Solid Tumors
Masegi Chinatsu0 个研究点目标入组 71 人开始时间: 2023年10月21日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 71
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
入选标准
- •-Patients who are >= 18 years old at the time of informed consent
- •-Patients who have disease measurable by RECIST v1.1
- •-Patients with an ECOG PS of 0 or 1
- •-Patients with a life expectancy of at least 3 months in the judgement of the investigator or subinvestigator
- •-The specified periods have passed respectively after the completion of the cancer treatments as of the date of enrollment
- •-Patients who agree to use a medically effective method of contraception
- •-Patients with histological or cytological evidence of at least one locally advanced or metastatic non-CNS solid tumor
- •-Patients with histological or cytological evidence of any of the following disease
- •- Gastric adenocarcinoma, GEJ adenocarcinoma, or esophageal adenocarcinoma
- •-Patients who are suitable for docetaxel treatment
排除标准
- •-Patients with an uncontrolled or serious intercurrent illness
- •-Patients with known active central nervous system metastasis
- •-Patients with a history of >= Grade 3 allergic reaction to any antibody drug
- •-Patients with a history of autoimmune disease
- •-Patients with a history of HIV, HBV, or HCV at screening
- •-Patients who have a history of primary immunodeficiency
- •-Patients with a history of treatment with docetaxel
研究者
相似试验
进行中（未招募）
1 期
Dose Escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Paediatric Participants With Solid TumoursCTIS2024-511071-16-00Glaxosmithkline Research & Development Limited147
招募中
1 期
A Study of AZD0486 in Subjects with Relapsed or Refractory B-Cell Non-Hodgkin LymphomaB-Cell Non-Hodgkin LymphomaJPRN-jRCT2041230077Misaki Masako9
进行中（未招募）
1 期
A Phase 1, Open-label , Dose EscalationStudy of Berubicin® in Pediatric Patientswith Progressive, Refractory, or Recurrent High GradeGliomasEUCTR2019-004016-58-PLWPD Pharmaceuticals Sp. z o.o.35
尚未招募
1 期
First in Human Multicenter Open Name Dose-increase,Consolidation method to Study Safety drug-level in Blood & drug metabolism Clinical Activity of Oral JBI-778 in Lung Cancer Patients with, without Brain Metastasis IDH Mutated WHO Grade 3,4 Recurrent Glioma, Salivary glands tumorCTRI/2024/07/070802Jubilant Therapeutics India Limited
招募中
1 期
A Phase-I dose escalation study to evaluate Safety of NRC-1111.CTRI/2023/03/051121ATCO Pharma Ltd